Perceptic Raises $12M Seed Funding to Transform Pharma AI
London-based Perceptic has emerged from stealth mode, announcing a successful $12 million seed funding round led by Accel. The innovative startup aims to develop a comprehensive AI platform that streamlines the entire drug development process, addressing the fragmentation currently plaguing the pharmaceutical industry.
Bridging the Gap in Drug Development
Founded in 2024 by former Palantir engineers Tilman Flock, Martin Copes, and Zaki Trache, Perceptic seeks to revolutionize how pharmaceuticals handle drug discovery and clinical development. The company’s platform integrates various stages of the drug lifecycle—asset scouting, scientific evaluation, indication selection, and clinical data analysis—into a single operational system.
The founders, who previously built Palantir’s AIP product and its Life Sciences practice, recognized the inefficiencies of existing systems where critical research insights often get lost between departments. Flock emphasized, “Too many critical drug development decisions still happen without a complete view of the evidence. Perceptic connects data, context, and decision-making so every insight compounds instead of dying at the next handoff.”
Significant Market Potential
The global AI in drug discovery market, valued at $1.72 billion in 2024, is projected to exceed $8.5 billion by 2030, growing at an impressive rate of over 30% annually. The high costs and lengthy timelines associated with drug development—averaging more than a decade and $2 billion per drug—underscore the urgency for more effective solutions.
Perceptic’s platform utilizes AI agents tailored to various data types, combining public knowledge with proprietary research and external datasets. Current clients, including the Australian biotechnology firm CSL, are already experiencing substantial improvements, with scientific due diligence reduced from weeks to hours.
Investors and Competitive Landscape
Led by Accel, which has a robust portfolio including Spotify and Dropbox, the funding round also saw participation from Air Street Capital and Elder Gull. Accel’s partner Sonali De Rycker noted the unique positioning of Perceptic, stating, “Perceptic is the first solution that follows the drug rather than the department.”
As Perceptic embarks on its journey, the company faces a rapidly consolidating competitive landscape. Notable competitors include Isomorphic Labs, which raised $2.1 billion in May 2026, and Insilico Medicine, which is also focused on AI-driven solutions for drug discovery. However, Perceptic is carving out a niche by building the connective tissue between various stages of drug development, potentially positioning itself as a leader in this emerging field.
Related
